IDEXX Laboratories, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Maintains Earnings Guidance for the Year 2015
Jul 30 15
IDEXX Laboratories, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $413,343,000 against $390,122,000 a year ago. Income from operations was $88,303,000 against $83,219,000 a year ago. Income before provision for income taxes was $81,603,000 against $80,742,000 a year ago. Net income attributable to stockholders was $56,912,000 or $0.60 per diluted share against $57,218,000 or $0.55 per diluted share a year ago.
For the six months, the company reported revenue of $795,820,000 against $750,325,000 a year ago. Income from operations was $161,106,000 against $153,265,000 a year ago. Income before provision for income taxes was $148,527,000 against $148,485,000 a year ago. Net income attributable to stockholders was $103,506,000 or $1.09 per diluted share against $103,803,000 or $1.00 per diluted share a year ago. Net cash provided by operating activities was $65,522,000 against $115,280,000 a year ago. Purchases of property and equipment were $46,873,000 against $25,410,000 a year ago.
For the year 2015, the company is maintaining its previous 2015 financial guidance, adjusted to account for the June 15, 2015 two-for-one stock split, as summarized below: revenue expected to be $1,600 million to $1,620 million, EPS expected to be $2.07 to $2.12, free cash flow expected to 80% to 90% of net income, capital expenditures expected to be $100 million. The company expects an effective tax rate of 30% and interest expense, net of interest income, of approximately $28 million reflecting current and projected borrowings.
IDEXX Laboratories, Inc. Announces Availability of Catalyst Total T4 Test for Both IDEXX Catalyst Dx Chemistry Analyzer and the IDEXX Catalyst One Chemistry Analyzer in North America
Jul 23 15
IDEXX Laboratories, Inc. announced the Catalyst Total T4 Test is now available for both the IDEXX Catalyst Dx Chemistry Analyzer and the IDEXX Catalyst One Chemistry Analyzer in North America. The Catalyst Total T4 Test enables veterinarians and technicians to provide clients with reliable and comprehensive results including thyroid function at the point of care. Veterinarians can add total T4 to any Catalyst Dx or Catalyst One test panel, allowing for a comprehensive chemistry, electrolyte and total T4 profile in one run with a single patient sample in approximately 15 minutes. With this announcement, the Catalyst Total T4 Test is available to Catalyst Dx customers. The Catalyst Dx and Catalyst One analyzers are part of IDEXX's comprehensive, integrated point-of-care and reference laboratory diagnostic solution.
IDEXX Laboratories Introduces Point-of-Care Antibody Test for Canine Leptospirosis Called the SNAP® Lepto Test
Jul 21 15
IDEXX Laboratories, Inc. announced the introduction of a point-of-care SNAP Lepto Test for dogs suspected of having leptospirosis, a potentially life-threatening and highly contagious bacterial infection. With results in 10 minutes, the SNAP Lepto Test will help veterinarians to diagnose and treat leptospirosis faster than ever before. Leptospirosis is a disease found worldwide that can infect both dogs and people. It most commonly affects young adult large-breed dogs that swim and run alongside wildlife hosts. Over the past 10 years, the disease has also been found in small dogs living in urban environments, likely due to encounters with rodents and wildlife hosts who have wandered into the city. Infected animals shed spirochetes in their urine that subsequently contaminate the environment. The prevalence of canine leptospirosis varies by region and season. Diagnosis of canine leptospirosis is often complicated and challenging. The symptoms are variable and common to other diseases. In addition, the most common testing method serology using the microscopic agglutination test (MAT) is so complex that it can take up to a week for results and is only performed at university or commercial laboratories. The point-of-care SNAP Lepto Test changes all of the above, providing a convenient diagnostic tool that enables veterinarians to detect antibodies to this infectious disease in 10 minutes. This advancement in diagnostic technology will empower veterinary clinics and pet owners to take necessary precautions against the spread of this contagious disease.
IDEXX Laboratories Elects Bruce L. Claflin as Director and Member of Audit Committee and Nominating and Governance Committee of the Board
Jul 14 15
IDEXX Laboratories, Inc. announced the unanimous election of Bruce L. Claflin as a member of the company's Board of Directors, effective July 14, 2015. In addition, Mr. Claflin will serve on the Audit Committee and the Nominating and Governance Committee of the Board. Mr. Claflin is the Chairman of the Board of Advanced Micro Devices, Inc. and a member of the board of directors of Ciena Corporation, and he previously served on the board of directors of Time Warner Telecom.
IDEXX Laboratories, Inc. to Report Q2, 2015 Results on Jul 30, 2015
Jul 13 15
IDEXX Laboratories, Inc. announced that they will report Q2, 2015 results at 7:00 AM, US Eastern Standard Time on Jul 30, 2015